Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020

Hampel, H., Listab, S., Teipelc, S. J., Garacie, F., Nisticòg, R., Blennowi, K., et al. (2014). Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochemical Pharmacology, 88(4), 426-449.

Item is

Dateien

einblenden: Dateien
ausblenden: Dateien
:
1-s2.0-S0006295213007405-main.pdf (Verlagsversion), 743KB
 
Datei-Permalink:
-
Name:
1-s2.0-S0006295213007405-main.pdf
Beschreibung:
-
OA-Status:
Sichtbarkeit:
Eingeschränkt (Max Planck Institute for Molecular Genetics, MBMG; )
MIME-Typ / Prüfsumme:
application/pdf
Technische Metadaten:
Copyright Datum:
2015-01-01
Copyright Info:
© 2015 Copyright Clearance Center, Inc. All Rights Reserved.
Lizenz:
-

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Hampel, Harald1, Autor
Listab, Simone 2, Autor
Teipelc, Stefan J.3, Autor
Garacie, Francesco 4, Autor
Nisticòg, Robert5, Autor
Blennowi, Kaj 6, Autor
Zetterbergi, Henrik 6, 7, Autor
Bertram, Lars8, Autor           
Duyckaertsl, Charles 9, Autor
Bakardjianm, Hovagim10, Autor
Drzezgao, Alexander11, Autor
Colliotp, Olivier 12, Autor
Epelbaumu, Stéphane13, Autor
Broich, Karl14, Autor
Lehéricy, Stéphane12, 15, Autor
Brice, Alexis12, Autor
Khachaturian, Zaven S. 16, Autor
Aisen , Paul S.17, Autor
Dubois , Bruno13, Autor
Affiliations:
1Université Pierre et Marie Curie, Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Pavillon François Lhermitte, Hôpital de la Salpêtrière, Paris, France, ou_persistent22              
2Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany, ou_persistent22              
3Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany, ou_persistent22              
4Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology, and Radiotherapy, University of Rome “Tor Vergata”, Rome, Italy, ou_persistent22              
5Department of Physiology and Pharmacology, University of Rome “La Sapienza”, Rome, Italy, ou_persistent22              
6Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, ou_persistent22              
7University College London Institute of Neurology, Queen Square, London, UK, ou_persistent22              
8Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1479655              
9Laboratoire de Neuropathologie Raymond-Escourolle, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France, ou_persistent22              
10IM2A – Institute of Memory and Alzheimer's Disease, Paris, France, ou_persistent22              
11Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany, ou_persistent22              
12Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l’Institut du Cerveau et de la Moelle Épinière, UMR-S975 Paris, France, ou_persistent22              
13Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié Salpêtrière, Paris, France, ou_persistent22              
14Federal Institute of Drugs and Medical Devices (BfArM), Bonn, Germany, ou_persistent22              
15IHU-A-ICM – Paris Institute of Translational Neurosciences Pitié-Salpêtrière University Hospital, , Paris, France, ou_persistent22              
16The Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020), Potomac, MD, USA, ou_persistent22              
17Department of Neurosciences, University of California, San Diego, San Diego, CA, USA, ou_persistent22              

Inhalt

einblenden:
ausblenden:
Schlagwörter: -
 Zusammenfassung: Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that “treatments” need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2013-12-222014-04-15
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Identifikatoren: -
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Biochemical Pharmacology
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Amsterdam, Boston : Elsevier
Seiten: - Band / Heft: 88 (4) Artikelnummer: - Start- / Endseite: 426 - 449 Identifikator: ISSN: 0006-2952
CoNE: https://pure.mpg.de/cone/journals/resource/954925384102